Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19058528 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18861616 | COLLAGEN HYDROLYSATE COMPOSITION FOR REDUCING JOINT PAIN AFTER EXERCISE | October 2024 | June 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18783156 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | July 2024 | June 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18750971 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | September 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18407929 | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND METHODS OF USE THEREOF | January 2024 | December 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18391146 | METHODS AND COMPOSITIONS FOR REGENERATING TISSUES | December 2023 | December 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18492150 | MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | October 2023 | July 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18279476 | LA PROTEIN AS A NOVEL REGULATOR OF OSTEOCLASTOGENESIS | August 2023 | November 2024 | Abandon | 15 | 1 | 1 | No | No |
| 18457861 | ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | August 2023 | March 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18352366 | TUNABLE SILK-BASED BIOMATERIALS WITH SACCHARIDE SUBSTITUTIONS, AND METHODS OF PRODUCING THE SAME | July 2023 | February 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18317277 | COMPOSITIONS FOR TREATING AUTOIMMUNE ARTHRITIS | May 2023 | August 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18301839 | MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN HUMANS AND IMPROVED CELL CULTIVATION METHODS | April 2023 | October 2024 | Allow | 18 | 3 | 1 | Yes | No |
| 18177642 | CARTILAGE-HOMING PEPTIDES | March 2023 | December 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18175849 | Methods of Using IL-1beta Compounds | February 2023 | February 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18175163 | TWISTED GASTRULATION POLYPEPTIDES AND USES THEREOF | February 2023 | July 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18114832 | IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS | February 2023 | September 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 18166211 | ANTI-SCLEROSTIN ANTIBODIES AND METHODS OF USE | February 2023 | September 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 18157689 | SAPOSIN C PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCER | January 2023 | September 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18088272 | DOSAGE REGIMEN FOR PEGYLATED INTERFERON | December 2022 | May 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18062608 | GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT | December 2022 | October 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 18046810 | COMPOSITIONS AND METHODS FOR TARGETED THERAPEUTIC DELIVERY TO BONE | October 2022 | January 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 17903910 | COMPOSITIONS AND METHODS FOR DEGENERATIVE DISC REGENERATION | September 2022 | March 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17663384 | INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE | May 2022 | September 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17698602 | BONE REPAIR PRODUCT AND METHODS OF USE THEREOF | March 2022 | February 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17616391 | ANTIBODY TARGETING THE VP-1 PROTEIN, FRAGMENTS THEREOF, AND USES OF SAME FOR DETECTING INFECTION WITH THE BK POLYOMAVIRUS | December 2021 | April 2025 | Allow | 40 | 0 | 0 | Yes | No |
| 17541992 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | December 2021 | September 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17517533 | Method of Treating Osteoarthritis | November 2021 | December 2024 | Allow | 37 | 3 | 1 | Yes | No |
| 17598049 | COMPOSITION FOR PROMOTING CARTILAGE TISSUE REGENERATION | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17438634 | A METHOD FOR IMMUNOSUPPRESSION | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17470455 | BIOMARKERS AND METHODS FOR ASSESSING PSORIATIC ARTHRITIS DISEASE ACTIVITY | September 2021 | January 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17465092 | METHOD FOR PURIFYING ACTIVE POLYPEPTIDES OR IMMUNOCONJUGATES | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17276916 | Human Monoclonal Antibody Binding Specifically to Human Hmgb1, and Pharmaceutical Composition for Treating or Preventing Alzheimer's Disease Containing Said Human Monoclonal Antibody | August 2021 | February 2025 | Allow | 47 | 0 | 1 | Yes | No |
| 17433295 | COMBINED THERAPIES OF ACTIVATABLE IMMUNE CHECKPOINT INHIBITORS AND CONJUGATED ACTIVATABLE ANTIBODIES | August 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17432185 | ANTI-CSP ANTIBODY VARIANTS | August 2021 | June 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17402325 | MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELL RELATED CANCER CELLS AND USES THEREOF | August 2021 | April 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17286355 | MARKER FOR DETERMING CRITICAL STAGE KIDNEY DISEASE | August 2021 | February 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17427559 | IMMUNOASSAY METHOD FOR FREE AIM IN BIOLOGICAL SAMPLE, AND ASSAY KIT | July 2021 | December 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17443012 | COMPOSITION AND METHOD FOR DELIVERY OF BMP-2 AMPLIFIER/CO-ACTIVATOR FOR ENHANCEMENT OF OSTEOGENESIS | July 2021 | August 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17422075 | ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVA | July 2021 | May 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17298865 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | June 2021 | November 2024 | Allow | 42 | 0 | 1 | Yes | No |
| 17290016 | BIOMARKER PROTEINS FOR DIAGNOSING ALZHEIMER'S DEMENTIA AND USE THEREOF | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17288234 | MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CD20 | April 2021 | August 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17287367 | ANTI-IL-25 ANTIBODIES AND USE THEREOF | April 2021 | December 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17232145 | CYCLIC PEPTIDE FROM NOVEL BONE MORPHOGENETIC PROTEIN 2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | April 2021 | August 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17282577 | MENISCUS REGENERATION MATERIAL | April 2021 | June 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17211261 | SYSTEMS, COMPOSITIONS, AND METHODS FOR TRANSPLANTATION | March 2021 | November 2024 | Abandon | 44 | 3 | 1 | Yes | No |
| 17279359 | AXL-SPECIFIC ANTIBODIES FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | March 2021 | December 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17256509 | ANABOLIC TARGETING STEM CELL GENE THERAPY FOR OSTEOPOROSIS | December 2020 | November 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17030416 | Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention | September 2020 | November 2024 | Abandon | 50 | 2 | 1 | Yes | No |
| 16967922 | METHODS FOR TREATING HETEROTOPIC OSSIFICATION | August 2020 | March 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 16945494 | METHODS OF REDUCING AGGREGATION OF IL-1RA | July 2020 | June 2025 | Abandon | 59 | 5 | 1 | Yes | No |
| 16960704 | CALRETICULIN BINDING CONSTRUCTS AND ENGINEERED T CELLS FOR THE TREATMENT OF DISEASES | July 2020 | December 2024 | Allow | 53 | 2 | 1 | Yes | No |
| 16760731 | HETEROTOPIC OSSIFICATION AND METHOD OF TREATMENT | April 2020 | October 2024 | Allow | 54 | 4 | 1 | Yes | No |
| 16863630 | INJECTABLE BONE MORPHOGENETIC PROTEIN | April 2020 | August 2024 | Allow | 52 | 4 | 1 | Yes | No |
| 16858301 | METHOD OF DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS | April 2020 | June 2025 | Allow | 60 | 6 | 1 | Yes | Yes |
| 16805481 | IL-4/IL-13 PATHWAY INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER | February 2020 | August 2024 | Allow | 54 | 3 | 1 | Yes | No |
| 16659604 | NON-RESORBABLE BONE ALLOGRAFTS AND METHOD FOR MAKING SAME | October 2019 | October 2023 | Abandon | 48 | 2 | 0 | Yes | No |
| 15855398 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES, CONDITIONS OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | December 2017 | September 2019 | Allow | 21 | 0 | 1 | Yes | No |
| 15553930 | ANTI-TGF-BETA ANTIBODY FOR THE TREATMENT OF FANCONI ANEMIA | August 2017 | August 2019 | Allow | 24 | 1 | 1 | Yes | No |
| 15165150 | ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR | May 2016 | April 2018 | Allow | 22 | 0 | 1 | Yes | No |
| 14757770 | Method of treating skeletal dysplasias using vessel dilator | December 2015 | February 2018 | Allow | 26 | 2 | 1 | Yes | No |
| 14875812 | BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF | October 2015 | June 2017 | Allow | 21 | 0 | 1 | Yes | No |
| 14767117 | HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF | August 2015 | October 2018 | Allow | 38 | 1 | 1 | Yes | No |
| 14812908 | Immunoconjugates for the Treatment of Tumours | July 2015 | June 2017 | Allow | 22 | 1 | 1 | Yes | No |
| 14759535 | A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders | July 2015 | March 2020 | Allow | 56 | 5 | 1 | Yes | No |
| 14626274 | COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION | February 2015 | June 2017 | Allow | 28 | 1 | 1 | Yes | No |
| 14419063 | METHODS FOR DIAGNOSING, PROGNOSING AND TREATING MUSCULAR DYSTROPHY | February 2015 | September 2017 | Allow | 31 | 2 | 1 | Yes | No |
| 14473339 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | August 2014 | September 2017 | Allow | 37 | 2 | 1 | Yes | No |
| 14368080 | PEPTIDES TARGETING RECEPTOR ACTIVATOR OF NUCLEAR FACTOR - KAPPA B (RANK) AND THEIR APPLICATIONS | June 2014 | March 2016 | Allow | 21 | 1 | 1 | Yes | No |
| 14004944 | INJECTABLE DELIVERY SYSTEM FOR HEPARAN-BINDING GROWTH FACTORS | September 2013 | November 2016 | Allow | 39 | 2 | 1 | Yes | No |
| 13989303 | HLA-G Isoform for use in the Treatment of a Disease Associated with Bone Resorption | August 2013 | February 2016 | Allow | 33 | 2 | 1 | Yes | No |
| 13947918 | Interleukin-B30 Proteins | July 2013 | February 2014 | Allow | 7 | 0 | 1 | Yes | No |
| 13803711 | BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF | March 2013 | July 2015 | Allow | 28 | 1 | 1 | Yes | No |
| 13644728 | Compositions and Methods for Increasing Bone Mineralization | October 2012 | November 2014 | Allow | 25 | 2 | 1 | Yes | Yes |
| 13595436 | USE OF CYTOKINE RECEPTORS AS BIOMARKERS AND THERAPEUTIC TARGETS IN HUMAN CANCER | August 2012 | June 2013 | Allow | 9 | 0 | 1 | Yes | No |
| 13497562 | TREATMENT OF CANCER | July 2012 | February 2016 | Allow | 47 | 3 | 1 | Yes | No |
| 13463018 | OSTEOGENIC DEVICE FOR INDUCING BONE FORMATION IN CLINICAL CONTEXTS | May 2012 | April 2015 | Allow | 36 | 2 | 1 | Yes | No |
| 13445759 | Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix Deposition | April 2012 | January 2017 | Allow | 57 | 4 | 1 | No | No |
| 13434629 | IL-B30 ANTIBODIES | March 2012 | March 2013 | Allow | 12 | 1 | 1 | Yes | No |
| 13380185 | AVIAN COLONY STIMULATING FACTOR 1 RECEPTOR BINDING PROTEINS | March 2012 | March 2016 | Allow | 51 | 4 | 1 | Yes | Yes |
| 13413242 | METHODS FOR TREATING CANCER USING PROSTATE SPECIFIC ANTIGEN AND TUMOR ENDOTHELIAL MARKER PEPTIDES | March 2012 | August 2013 | Allow | 17 | 1 | 1 | Yes | No |
| 13375562 | COMPOUNDS AND METHODS FOR TREATING BONE DISORDERS AND CONTROLLING WEIGHT | February 2012 | August 2015 | Allow | 44 | 3 | 2 | Yes | No |
| 13344509 | MODIFIED DEFENSINS AND THEIR USE | January 2012 | August 2013 | Allow | 19 | 1 | 1 | No | No |
| 13343127 | Methods for Promoting Wound Healing and/or Reducing Scar Formation | January 2012 | February 2014 | Allow | 25 | 2 | 1 | Yes | No |
| 13122637 | MODULATION OF THE ACTIVITY AND DIFFERENTIATION OF CELLS EXPRESSING THE OSTEOCLAST-ASSOCIATED RECEPTOR | October 2011 | November 2013 | Allow | 32 | 1 | 1 | Yes | No |
| 13246197 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | September 2011 | January 2014 | Allow | 27 | 2 | 1 | Yes | No |
| 13169641 | USE OF CYTOKINE RECEPTORS AS BIOMARKERS AND THERAPEUTIC TARGETS IN HUMAN CANCER | June 2011 | June 2012 | Allow | 11 | 0 | 1 | Yes | No |
| 13167431 | CO-TARGETING OF AURORA A KINASE AND LIM KINASE 1 FOR CANCER THERAPY | June 2011 | September 2013 | Allow | 26 | 2 | 1 | Yes | No |
| 13140931 | ANTI PERIODONTITIS-CAUSING MICROORGANISM AGENT AND MEDICAL OR DENTAL MATERIALS USING THE SAME | June 2011 | June 2016 | Allow | 60 | 4 | 1 | Yes | No |
| 13044607 | AFFINITY PEPTIDES TOWARD BMP-2 | March 2011 | May 2013 | Allow | 26 | 2 | 1 | Yes | No |
| 12996260 | POLYPEPTIDE | February 2011 | November 2015 | Allow | 60 | 2 | 1 | Yes | No |
| 11992234 | MODULATION OF OSTEOCLAST DIFFERENTIATION | February 2011 | May 2014 | Allow | 60 | 2 | 1 | Yes | No |
| 12930858 | INHIBITOR PROTEIN OF THE WNT SIGNAL PATHWAY | January 2011 | February 2013 | Allow | 25 | 3 | 1 | Yes | No |
| 12909405 | CHIMERIC ANTIGEN-SPECIFIC T CELL-ACTIVATING POLYPEPTIDES | October 2010 | April 2014 | Allow | 42 | 1 | 0 | Yes | No |
| 12902994 | COMPONENT OF BROMELAIN | October 2010 | January 2017 | Allow | 60 | 6 | 1 | Yes | No |
| 12819583 | USE OF CALCITONIN IN OSTEOARTHRITIS | June 2010 | September 2013 | Allow | 39 | 2 | 1 | Yes | No |
| 12771696 | IMMUNOCONJUGATES FOR THE TREATMENT OF TUMOURS | April 2010 | April 2015 | Allow | 60 | 4 | 1 | Yes | Yes |
| 12756995 | METHOD FOR BONE MARROW PRESERVATION OR RECOVERY | April 2010 | March 2016 | Allow | 60 | 6 | 2 | No | No |
| 12730469 | Methods and Devices for Correcting Spinal Deformity With Pharmaceutical-Eluting Pedicle Screws | March 2010 | December 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12704187 | TREATMENT OF OSTEOPOROSIS IN PERI- AND POST- MENOPAUSAL WOMEN WITH HEPCIDIN | February 2010 | December 2014 | Allow | 58 | 2 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner XIE, XIAOZHEN.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner XIE, XIAOZHEN works in Art Unit 1674 and has examined 170 patent applications in our dataset. With an allowance rate of 88.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.
Examiner XIE, XIAOZHEN's allowance rate of 88.2% places them in the 65% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by XIE, XIAOZHEN receive 2.22 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by XIE, XIAOZHEN is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +25.2% benefit to allowance rate for applications examined by XIE, XIAOZHEN. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 28.4% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 40.7% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 88.0% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 86.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 36.8% are granted (fully or in part). This grant rate is in the 33% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 17.1% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.